Pharma Pulse 11/21/24: A Global Standard for Data Sources, 75% of Adults are Obese & more

Creating a Global Standard for Data Sources
Mark Melton, vice president of biospecimen data and operations, Slope, highlights the clinical research industry’s need for more regulation around collecting data.

Study Finds Nearly 75% of Adults 25 and Older Have Overweight or Obesity
If patterns and trends were to continue, the authors predict that nationwide overweight and obesity prevalence in adults will surpass 80% by 2050.

Health Care Roundup: Market Talk
European defense and pharmaceutical stocks are expected to perform strongly beyond 2025, Moody’s analysts Martin Kohlhase and Marina Albo say in a note to investors. Europe’s defense companies continue to benefit from structural demand drivers that are unlikely to abate in the next years, they say. Their order books are strong and cover between two and five years of revenue, they write. Global supply-chain challenges affecting aerospace and defense companies pose the main risk to Moody’s double-digit percentage operating profit growth forecast for 2025, they note.

Trump Picks Oz for CMS Administrator
Mehmet Oz, M.D., is another unconventional pick by Trump and is perhaps another an indication that Trump intends to let his HHS secretary nominee, Robert F. Kennedy Jr., "go wild on health."

Sam Clark, MD, PhD on LinkedIn
I really enjoyed speaking with Pharmaceutical Executive about the recent FDA approval of Bristol Myers Squibb’s #schizophrenia drug Cobenfy (formerly KarXT). This approval is exciting as it opens the door to further innovations in the space. With our program TerXT, a combination of novel prodrugs of xanomeline and trospium (the two active compounds in Cobenfy), we are pursuing an accelerated 505(b)(2) development pathway with the goal of delivering once-daily form of the drug as well as a multi-month long-acting injectable form.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs